Cited by 270Acute Lymphoblastic Leukemia researchGlobal Cancer Incidence and ScreeningLymphoma Diagnosis and Treatment

Racial and ethnic differences in survival of children with acute lymphoblastic leukemia

Open access
Bhatia, Smita, Sather, Harland N., Heerema, Nyla A., Trigg, Michael E., Gaynon, Paul S., Robison, Leslie L.·2002·Blood

Abstract

Black children with acute lymphoblastic leukemia (ALL) have poor outcomes, but limited information is available for children from other racial and ethnic backgrounds, such as Hispanic and Asian. We undertook a retrospective cohort study of children with ALL treated on Children's Cancer Group therapeutic protocols to determine outcomes by racial and ethnic backgrounds of patients treated with contemporary risk-based therapy. In total, 8447 children (white, n = 6703; Hispanic, n = 1071; black, n = 506; and Asian, n = 167) with newly diagnosed ALL between 1983 and 1995 were observed for a median of 6.5 years. Analysis of disease outcome was measured as overall survival (OS) and event-free survival (EFS) and was adjusted for known predictors of outcome including clinical features, disease biology, socioeconomic status, and treatment era (1983-1989 vs 1989-1995). There was a statistically significant difference in survival by ethnicity (P < .001). Five-year EFS rates were: Asian, 75.1% ± 3.5%; white, 72.8% ± 0.6%; Hispanic, 65.9% ± 1.5%; and black, 61.5% ± 2.2%. Multivariate analysis revealed that when compared with white children, black and Hispanic children had worse outcomes and Asian children had better outcomes after adjusting for known risk factors. The poorer outcomes among black children were most apparent among patients with standard-risk features (relative risk [RR], 2.0; 95% confidence interval [CI], 1.6-2.5), whereas poorer outcomes in Hispanic children (RR, 1.4; 95% CI, 1.2-1.6) were most evident among patients with high-risk features. Asian children had better outcomes than all racial and ethnic groups among high-risk patients, particularly in the recent era (5-year EFS, 90.9% ± 6.1%). Racial and ethnic differences in OS and EFS persist among children with ALL who receive contemporary risk-based therapy. Future studies should focus on reasons—perhaps compliance or pharmacogenetics—for those differences.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2002-02-0395

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Ancestry is likely to also impact the risk and severity of late effects.

    “Similarly, ancestry, which is known to alter both pediatric ALL incidence and survival (Abrahão et al., 2015; Goggins & Lo, 2012; Linabery, Johnson, & Ross, 2012), is likely to also impact the risk and severity of late effects (Bhatia et al., 2002; Dores, Devesa, Curtis, Linet, & Morton, 2012; Lim, Bhatia, Robison, & Yang, 2014; Yang et al., 2010).”

    From Brain structure, working memory and response inhibition in childhood leukemia survivors (2017) · cites this paper as Bhatia et al., 2002

    The Discussion reports racial and ethnic differences in survival and speculates about differences in drug metabolism, but does not address the risk or severity of late effects. The Statistical analysis section defines the outcomes as overall and event-free survival, not late effects; searches for late effects, long-term complications, and treatment toxicity found no passage supporting the attributed point. Page numbers were not available in our copy. (LLM, conf=0.74)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 47 references couldn’t be matched to a known paper.

Research works printed but not linked: 14

  1. Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States: sex-, race-and 1-year age-specific rates by histologic type. Cancer. 1995;75:2186-2195.
  2. Pui C-H, Evans WE. Acute lymphoblastic leuke- mia. N Engl J Med. 1998;339:605-615.
  3. Foucar K, Duncan MH, Stidley CA, Wiggins CL, Hunt WC, Key CR. Survival of children and ado- lescents with acute lymphoid leukemia: a study of American Indians and Hispanics and non-His- panic whites treated in New Mexico (1969 to 1986). Cancer. 1991;67:2125-2130.
  4. Hord MH, Smith TL, Culbert SJ, Frankel LS, Pinkel DP. Ethnicity and cure rates of Texas chil- dren with acute lymphoid leukemia. Cancer. 1996;77:563-569.
  5. Walters TR, Bushore M, Simone J. Poor progno- sis in Negro children with acute lymphocytic leu- kemia. Cancer. 1972;29:210-214.
  6. Reaman GH, Leikin SL. Racial variation in the frequency of immunological subtypes of child- hood acute lymphoblastic leukemia. Prog Cancer Res Ther. 1984;27:163-168.
  7. Falletta JM, Boyett J, Pullen DJ, et al. Clinical and phenotypic features of childhood acute lympho- cytic leukemia in whites, blacks, and Hispanics: a Pediatric Oncology Group study. Prog Cancer Res Ther. 1984;27:191-195.
  8. Ries LAG, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK, eds. SEER Cancer Statis- tics Review, 1973-1996. Bethesda, MD: National Cancer Institute; 1999.
  9. Hutchinson RJ, Neerhout RC, Bertolone S. Should therapy be intensified for patients with good risk ALL [abstract]? Blood. 1996;88:668.
  10. Lange B, Sather H, Weetman R, et al. Double delayed intensification improves outcome in mod- erate risk pediatric acute lymphoblastic leukemia (ALL): a Children's Cancer Group study, CCG- 1891 [abstract]. Blood. 1997;90:559.
  11. Steinherz PG, Gaynon PS, Breneman JC, et al. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic fea- tures: randomized controlled trial from the Chil- dren's Cancer Group. Cancer. 1998;82:600-612.
  12. Smith M, Arthur D, Camitta B, et al. Uniform ap- proach to risk classification and treatment assign- ment for children with acute lymphoblastic leuke- mia. J Clin Oncol 1996;14:18-24.
  13. Kelsey JL, Thomson WD, Evans AS, eds. Meth- ods in Observational Epidemiology: Retrospec- tive Cohort Studies. New York, NY: Oxford Uni- versity Press; 1986.
  14. Williams D, Harber J, Murphy S, et al. Chromo- somal translocations play a unique role in influ- encing prognosis in childhood acute lymphoblas- tic leukemia. Blood. 1986;68:205-212.

Cited by

Sorted by citations

Authors
Bhatia, S., Sather, H. N., Heerema, N. A., Trigg, M. E., Gaynon, P. S., & Robison, L. L.
Affiliations
University of Southern California (US)
Corresponding author
Bhatia, Smita
Venue
Blood
Published
2002-09-15
Volume
100
Issue
6
Pages
1957-1964
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W1995246501
Cited by
270
References
47
Citations by year
2026: 6 · 2025: 8 · 2024: 9 · 2023: 11 · 2022: 15 · 2021: 14 · 2020: 25 · 2019: 12 · 2018: 11 · 2017: 12 · 2016: 13 · 2015: 12 · 2014: 18 · 2013: 10 · 2012: 17
FWCI
8.68
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Cancer Institute (U10CA013539, 5U10 CA 13539-2652)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Acute Lymphoblastic Leukemia research
  • Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords
acute lymphoblastic leukemia, racial disparities, ethnic differences, children, overall survival, event-free survival, Hispanic children, Black children, Asian children, socioeconomic status, pharmacogenetics, medication adherence
MeSH terms
Adolescent, Child, Child, Preschool, Chromosome Aberrations, Ethnicity, Female, Follow-Up Studies, Humans, Infant, Male, Prospective Studies, Retrospective Studies, Risk Factors, Social Class, Survival Analysis, Treatment Outcome, Disease-Free Survival, Racial Groups, Precursor Cell Lymphoblastic Leukemia-Lymphoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review